The Global CIS Insulin Industry is on track to achieve a significant milestone, with a projected valuation of US$ 600 Million by 2032, as per the latest insights unveiled by FMI. The industry has demonstrated steady growth, securing US$ 465 Million in 2022 and reflecting a notable 2.2% Compound Annual Growth Rate (CAGR) from 2015 to 2021, reaching a valuation of US$ 455 Million.
Governments worldwide are actively supporting the CIS insulin market, acting as a catalyst for its continuous growth in the years to come. This substantial backing is anticipated to further fuel the industry’s expansion, rendering it a highly lucrative sector for investors and stakeholders alike.
The trajectory of the market is significantly influenced by a surge in initiatives aimed at delivering high-quality diagnoses, intensifying the demand for CIS insulin. The increasing prevalence of diabetes, coupled with evolving lifestyles and dietary habits contributing to health issues such as obesity and other metabolic diseases, is expected to be a key driver for market growth soon.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-15202
Key Takeaways from the Global CIS Insulin Industry Study
- Global CIS Insulin Industry worth to grow 1.3x during the 2022-2032 period of assessment
- By product type, the rapid-acting segment is expected to record a 2.2% CAGR by 2032
- By application, the Type I and other diabetes segment to expand at a 2.1% growth rate during the forecast period
- The U.S market to garner US$ 257 Million and record a 4.6% CAGR from 2022-2032
- Market in China to procure US$ 50 Million, expanding at a 4.5% growth rate during the assessment period
“With a rising global incidence of diabetes, healthcare practitioners are extensively leveraging diagnostics and treatment technologies aimed at providing maximum relief to patients. This has widened prospects for CBD insulin products,” remarks an FMI analyst.
Global CIS Insulin Industry Competitive Landscape
Eminent players in the Global CIS Insulin Industry include Novo Nordisk, Sanofi, Eli Lilly, Bristol-Myers Squibb, and Novartis among others. Recent key developments among players include:
- In June 2022– Lilly presented the new mechanism of action data and new analyses of Mounjaro™ (tripeptide) injection for the treatment of adults with type 2 diabetes at the American Diabetes Association’s®’s 82nd Scientific Sessions.
- In November 2021– Novo Nordisk announced the acquisition of Dicerna Pharmaceuticals (Dicerna). to discover and develop RNAi therapies using Dicerna’s proprietary GalXC™ RNAi platform technology.
- In February 2022 — Novartis India Limited (NIL)today announced an exclusive sales and distribution agreement with Dr. Reddy’s Laboratories (Dr. Reddy’s) for a few of its Established Medicines which includes the Voveran range, the Calcium range, and Methergine.
- In January 2022– Bristol Myers Squibb and Century Therapeutics announced a collaboration and license agreement to develop and commercialize up to four induced pluripotent stem cell (“iPSC”) derived, engineered natural killer cell (“iNK”) and/or T cell (“iT”) programs for hematologic malignancies and solid tumors.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the Global CIS Insulin Industry presenting a historical analysis from 2015 to 2021 and forecast statistics for the period of 2022-2032.
The study reveals essential insights based on Product (Rapid Acting, Long Acting, Premixed, Premixed Analog, Short-Acting, Intermediate-Acting) by Application (Type I and other diabetes, Type II diabetes) by Source (Human Recombinant Insulin, Analogs) and Region (North America, Latin America Europe, APAC, and Middle East & Africa)
Click Here To Buy Your Detailed Report
https://www.futuremarketinsights.com/checkout/15202
Key Segments Profiled in the CIS Insulin Industry Survey
Global CIS Insulin Industry by Product Type:
- Rapid Acting CIS Insulin
- Long Acting CIS Insulin
- Premixed CIS Insulin
- Premixed Analog CIS Insulin
- Short-Acting CIS Insulin
- Intermediate-Acting CIS Insulin
Global CIS Insulin Industry by Application:
- CIS Insulin for Treating Type I and Other Diabetes
- CIS Insulin for Treating Type II Diabetes
Global CIS Insulin Industry by Source:
- Human Recombinant CIS Insulin
- Analogs-based CIS Insulin
Global CIS Insulin Industry by Region:
- North America CIS Insulin Market
- Latin America CIS Insulin Market
- Europe CIS Insulin Market
- Asia & Pacific CIS Insulin Market
- Middle East & Africa (MEA) CIS Insulin Market
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube